



Association Between Interleukin-8 Levels in Bronchoalveolar Lavage Fluid and its Correlation with Severity in Children With Bronchiectasis

Thesis

Submitted for Partial Fulfillment of the MD
Degree in Pediatrics

By

Shaimaa Ahmed Salah Hegazy
M.B.B.Ch, Faculty of Medicine, Ain Shams University

Under Supervisors

Prof. Magda Yehia El Seify

Professor of Pediatrics
Faculty of Medicine – Ain Shams University

Prof. Tharwat Ezat Deraz

Professor of Pediatrics
Faculty of Medicine – Ain Shams University

Prof. Laila Abdel Ghaffar Hegazy

Professor of Pediatrics
Faculty of Medicine – Ain Shams University

Prof. Manal Mohamed Abd Al Aziz

Professor of Clinical Pathology
Faculty of Medicine – Ain Shams University

Ass. Prof. Asmaa Al Hussein Ahmed

Assistant Professor of Pediatrics
Faculty of Medicine – Ain Shams University

Faculty of Medicine
Ain Shams University

2019

بِسْمِ اللَّهِ الرَّحْمَنِ الرَّحِيمِ

قَالَ

لَسْبِقَانِكَ لَا عِلْمَ لَنَا
إِلَّا مَا عَلَّمْتَنَا إِنَّكَ أَنْتَ
الْعَلِيمُ الْعَظِيمُ

صدق الله العظيم

سورة البقرة الآية: ٣٢



First of all, thanks to **Allah** whose magnificent help was the main factor in completing this work.

No words could express my deepest thanks and appreciation to **Prof. Magda Yehia El Seify**, Professor of Pediatrics, Faculty of Medicine, Ain Shams University, for inspiring me with the idea of this work. Her patience, precious advice and guidance enlightened my way throughout this work.

I want also to express my profound gratitude to **Prof. Tharwat Ezat Deraz**, Professor of Pediatrics, Faculty of Medicine, Ain Shams University, for his patience, valuable advice and continuous help in completing this work.

I am also deeply indebted to **Prof. Laila Abdel Ghaffar Hegazy**, Professor of Pediatrics, Faculty of Medicine, Ain Shams University, for her kind help, guidance, useful advices, continuous encouragement and support all through my entire work.

I want to express my profound and sincere gratitude to **Prof. Manal Mohamed Abd Al Aziz**, Professor of Clinical Pathology, Faculty of Medicine, Ain-Shams University, for her kind support and supervision of this work.

My deepest thanks and gratitude to **Ass. Prof. Asmaa Al Hussein Ahmed**, Assistant Professor of Pediatrics, Faculty of Medicine, Ain-Shams University, for her time and efforts in supervision of this work.

Finally, my deepest thanks to all my family and colleagues who helped me in the production of this work.

Contents

<i>Subjects</i>	
<i>Page</i>	
List of abbreviations.....	II
List of figures.....	IV
List of tables.....	VI
• Introduction	1
• Aim of the Work	3
• Review of Literature	
♦ Chapter (1): Bronchiectasis.....	4
♦ Chapter (2): Bronchoscopy and Bronchoalveolar Lavage.....	60
♦ Chapter (3): Interleukin 8.....	68
• Patients and Methods	73
• Results	82
• Discussion	99
• Summary and Conclusion	106
• Recommendations	108
• References	110
• Arabic Summary	

List of Abbreviations

ACTs	: Airway Clearance Techniques
AIDS	: Acquired immune deficiency syndrome
BAL	: Bronchoalveolar lavage
BE	: Bronchiectasis
CF	: Cystic fibrosis
CFTR	: CF transmembrane conductance regulator
cHRCT	: Chest High-Resolution Computed Tomography
CRP	: C-reactive protein
CSLD	: Chronic suppurative lung disease
CXCR2	: Chemokine Receptor 2
DPB	: Diffuse panbronchiolitis
FAE	: Flexible airway endoscopy
HRCT	: High-resolution computed tomography
HVMA	: High-speed video microscopy analysis
ICS	: Inhaled corticosteroids
LABA	: Long-acting beta2- agonist
MMP	: Matrix metalloproteinase
MRI	: Magnetic resonance imaging
MVCC	: Mutation Varying clinical consequence
NBS	: Newborn screening
NCFB	: Non-cystic fibrosis bronchiectasis
NE	: Neutrophil elastase
NTHi	: Non-typeable H. influenza

List of Abbreviations

NTM	: Nontuberculous mycobacteria
Pa	: Pseudomonas aeruginosa
PBB	: Protracted bacterial bronchitis
PCD	: Primary ciliary dyskinesia
PIDs	: Primary immunodeficiency disorders
rhDNase	: Recombinant human deoxyribonuclease
SAA	: Serum amyloid A
sTREM-1	: Soluble triggering receptor expressed on myeloid cells-1
TEM	: Transmission electron microscopy
TIMPs	: Tissue inhibitors of metalloproteinases
TNF-alpha	: Tumor necrosis factor-alpha

List of Figures

<u>No.</u>	<u>Figure</u>	<u>Page</u>
<u>1</u>	CF is diagnosed when an individual has both a clinical presentation of the disease and evidence of CFTR dysfunction.	11
<u>2</u>	Two images from the same individual with tracheobronchomegaly showing a) gross tracheal dilatation and b) severe central bronchiectasis	18
<u>3</u>	Radiological characteristics and aetiology	23
<u>4</u>	Pathogenesis of bronchiectasis	31
<u>5</u>	Prevalence's of several common respiratory pathogens CF as a function of age	34
<u>6</u>	Bronchiectasis CT-morphology	39
<u>7</u>	Two patients are shown: a) a patient with moderate idiopathic bronchiectasis demonstrating predominantly cylindrical dilatation, b) a patient with severe disease and <i>Pseudomonas aeruginosa</i> colonisation demonstrating widespread varicose and cystic bronchial dilatation.	39
<u>8</u>	Management of NCFB	49
<u>9</u>	Treatment for bronchiectasis considered in this guideline according to the vicious cycle concept of bronchiectasis	50
<u>10</u>	Therapeutic scheme for bronchiectasis	54

List of Figures

<u>No.</u>	<u>Figure</u>	<u>Page</u>
<u>11</u>	Chest HRCT (A and B) and bronchoscopy (C and D) in a child with bronchiectasis. (C and D) bronchoscopy findings.	67
<u>12</u>	Major biological activities of IL-8/CXCL8 LTB ₄ , leukotriene B ₄ ; MMP-9 matrix metalloproteinase-9.	71
<u>13</u>	Dyspnea grade.	85
<u>14</u>	Sweat chloride.	87
<u>15</u>	Radiological score.	87
<u>16</u>	Pseudomonas cultures.	89
<u>17</u>	Bacteria cultures.	89

List of Tables

<u>No.</u>	<u>Table</u>	<u>Page</u>
<u>1</u>	Most common causes and associations of NCFB in pediatric age	13
<u>2</u>	Common infectious causes of bronchiectasis	15
<u>3</u>	Most frequent conditions associated with children bronchiectasis	24
<u>4</u>	Clinical characteristics and aetiology of bronchiectasis	25
<u>5</u>	Most common findings of NCFB in children	37
<u>6</u>	Suggested staged immunological investigations of patients with bronchiectasis	42
<u>7</u>	British thoracic society Guidelines on non-cystic fibrosis bronchiectasis	43
<u>8</u>	Basic investigations for children with bronchiectasis	44
<u>9</u>	Clinical microbiological and radiological features used to assess disease severity	46
<u>10</u>	Signs and symptoms frequently associated with a clinical exacerbation of pediatric bronchiectasis	48
<u>11</u>	Treatments for bronchiectasis	59
<u>12</u>	Indications of bronchoscopy	64
<u>13</u>	Proinflammatory and immune mediators upregulated during bronchiectasis	72

List of Tables

<u>No.</u>	<u>Table</u>	<u>Page</u>
<u>14</u>	Bhalla score.	77
<u>15</u>	Demographic data within whole group.	83
<u>16</u>	Clinical severity within whole group.	84
<u>17</u>	Lab investigations within whole group.	86
<u>18</u>	BALF markers within whole group.	88
<u>19</u>	Type of bacteria in BALF culture	90
<u>20</u>	IL8 and clinical severity.	91
<u>21</u>	IL8 and lab investigations.	93
<u>22</u>	Correlation between IL8 and demographic data and clinical severity.	96
<u>23</u>	Correlation between IL8 and lab investigations.	97
<u>24</u>	Correlation between IL8 levels and BAL cytology.	98

Introduction

Bronchiectasis is a complex chronic respiratory condition resulted from a vicious cycle of chronic infection and airway inflammation leading to permanent dilatation of the bronchial lumen with permanent lung tissue damage and progressive decline in lung function and is associated with significant morbidity in children that extend beyond the respiratory system and include cardiac and psychological effects (**Pizzutto et al., 2017**).

Clinical and functional features of bronchiectasis are chronic wet cough which is usually the commonest finding, exertional dyspnea, hemoptysis, digital clubbing, and chest wall deformities. Recurrent wheezing and growth failure are additional symptoms that may be found. Repeated episodes of pulmonary exacerbations are associated with progressive decline in lung function and reduced quality of life (**Gallucci et al., 2017**).

Chronic neutrophil-dominant airway inflammation is a key feature of bronchiectasis and activated neutrophils represent a key component of the “vicious cycle” of lung damage through the release of their harmful cellular contents, particularly, cell-derived proteases and reactive oxygen species (**Chalmers et al., 2015**).

In addition, airway secretions in patients with BE is rich in potent neutrophilic chemoattractant cytokines, including IL-1b, tumor necrosis factor-a, IL-8, and leukotriene B4 produced by the stimulatory effects of hyperactive alveolar macrophages. This persistent cytokine milieu results in chronic neutrophilic recruitment to the alveoli and progressive tissue damage (**Derek et al., 2016**).

Bronchoscopy is indicated in cases of bronchiectasis as recommended by The British Thoracic Society in 2010, it is useful for sampling of lower respiratory tract secretions and obtaining microbiological results in patients and for obtaining endobronchial biopsy of airway cilia to investigate causes of bronchiectasis (**Pasteur, 2010**).

The evaluation of cellularity is one of the principal indications for BAL, from the alveolar environment. The analysis of cytokines, as well as of pro- and anti-inflammatory molecules, in the BAL fluid is also the focus of increasing interest, both in clinical practice and research.

Aim of the Work

The aim of this study is to evaluate the degree of bronchial inflammation in patients with bronchiectasis by measuring the levels of airway interleukin-8 as an inflammatory biomarker and assessment of bronchoalveolar lavage fluid neutrophilic count to correlate their values with disease severity.

Chapter (1)

Bronchiectasis

Bronchiectasis (BE) is a heterogeneous disease associated with significant morbidity in children that extend beyond the respiratory system and include cardiac and psychological effects and is defined as a complex chronic respiratory condition in which an area of the bronchial lumen is permanently and abnormally widened, with accompanying chronic infection, airway inflammation, and progressive decline in lung function **(Pizzutto et al., 2017)**.

Bronchiectasis is found in a variety of pulmonary diseases and is caused by long-term excessive inflammatory damage to the airways, which results in tissue breakdown, structural modification in the bronchial wall and remodeling resulting in permanent irreversible dilation of the bronchial lumen, and the key clinical symptoms of chronic productive cough and shortness of breath **(Martínez-García et al 2017), (Schäfer et al., 2018)**.

Incidence and prevalence:

The introduction of high-resolution computed tomography (HRCT) and the advances in diagnostic techniques resulted in diagnosing bronchiectasis earlier and at earlier stages leading to an apparent increase in the prevalence of bronchiectasis worldwide with some countries reporting childhood fatalities, and a growing appreciation of economic cost (**Gallucci et al., 2017**).

The prevalence of bronchiectasis in the United States and worldwide is unknown and the true disease burden from the disease in children is difficult to ascertain as the diagnosis is often delayed and depends upon the populations studied, physician awareness, and availability of cHRCT scans (**Marcella Gallucci, et al. 2016**).

The incidence among European populations is estimated to be around 0.2 / 100,000 in UK and 2,3/100,000 in Ireland but globally, the prevalence of chronic suppurative lung disease (CSLD) in high-income countries over the last 50 years has declined with the introduction of antibiotics, immunizations, improved hygiene, nutrition, and access to medical care (**McCallum and Binks, 2017**).

However, a substantial burden of CSLD still persists among socially disadvantaged populations of high-income
